R Eliakim
Overview
Explore the profile of R Eliakim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
2934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leenhardt R, Koulaouzidis A, McNamara D, Keuchel M, Sidhu R, McAlindon M, et al.
Clin Res Hepatol Gastroenterol
. 2021 Mar;
45(6):101637.
PMID: 33662785
Background And Aim: Although recommended, the P-score used for assessing the pertinence / relevance of findings seen in small bowel (SB) capsule endoscopy (CE) is based on a low level...
2.
Ben-Horin S, Ungar B, Kopylov U, Lahat A, Yavzori M, Fudim E, et al.
Aliment Pharmacol Ther
. 2018 Feb;
47(8):1117-1125.
PMID: 29446098
Background: Data on combination-biologic treatment in (IBD) are still scant. Aim: To explore outcomes of patients co-exposed to anti-TNF and vedolizumab. Methods: Patients starting vedolizumab having measurable anti-TNF levels after...
3.
Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, et al.
Aliment Pharmacol Ther
. 2017 Nov;
47(2):212-218.
PMID: 29124774
Background: Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have...
4.
Engel T, Ungar B, Ben-Haim G, Levhar N, Eliakim R, Ben-Horin S
United European Gastroenterol J
. 2017 Oct;
5(6):880-886.
PMID: 29026602
Background: Non-adherence to medication in patients with inflammatory bowel disease (IBD) is a challenging problem which is often overlooked or under-estimated by the physician or denied by the patient. We...
5.
Klang E, Kopylov U, Eliakim R, Rozendorn N, Yablecovitch D, Lahat A, et al.
Clin Radiol
. 2017 May;
72(9):798.e7-798.e13.
PMID: 28506799
Aim: To investigate the role of restricted diffusion in quiescent Crohn's disease (CD) patients and its association with inflammatory biomarkers and endoscopic disease. Material And Methods: Fifty-two quiescent CD patients...
6.
Yablecovitch D, Oren A, Ben-Horin S, Fudim E, Eliakim R, Saker T, et al.
Dig Dis Sci
. 2016 Dec;
62(3):755-760.
PMID: 28025744
Background: Syndecan-1 (SDC1) is essential for maintaining normal epithelial barrier. Shedding of SDC1 ectodomain, reflected by serum soluble syndecan-1 (SSDC1) levels, is regulated by inflammation. Increased intestinal permeability plays a...
7.
Ungar B, Kopylov U, Engel T, Yavzori M, Fudim E, Picard O, et al.
Aliment Pharmacol Ther
. 2016 Nov;
45(2):276-282.
PMID: 27862102
Background: Anti-adalimumab antibodies (AAA) are associated with loss of clinical response (LOR). Addition of an immunomodulator has been shown to reverse immunogenicity and regain response with infliximab monotherapy. Similar data...
8.
Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, et al.
Aliment Pharmacol Ther
. 2016 Apr;
43(12):1293-9.
PMID: 27091119
Background: Infliximab is effective as salvage therapy for patients with steroid refractory acute severe ulcerative colitis (UC). Although current data suggest that the pharmacokinetics of infliximab are influenced by inflammatory...
9.
Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, et al.
Aliment Pharmacol Ther
. 2015 Jun;
42(3):356-64.
PMID: 26032402
Background: Low drug levels are associated with emerging loss of response to anti-TNF. However, this may not be the case in patients with long-term remission. Aim: To investigate the outcome...
10.
Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, et al.
Am J Gastroenterol
. 2015 Apr;
110(4):608.
PMID: 25853210
No abstract available.